Britannia Life Sciences Inc.
BLSIF
$0.06
$0.03100.00%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -60.98% | -52.79% | 7.82% | -- | -90.97% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -60.98% | -52.79% | 7.82% | -- | -90.97% |
| Cost of Revenue | -72.16% | -7.48% | 146.51% | -- | -82.92% |
| Gross Profit | -41.89% | -75.55% | -71.65% | -- | -95.00% |
| SG&A Expenses | -39.88% | 105.78% | -11.20% | -- | -44.70% |
| Depreciation & Amortization | 3.67% | 4.55% | 5.61% | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -43.37% | 82.18% | 7.58% | -- | -56.86% |
| Operating Income | 38.59% | -236.16% | -7.47% | -- | -1,925.51% |
| Income Before Tax | 4,237.85% | 71.55% | 25.05% | -- | -177.91% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 3,684.19% | 71.55% | 25.05% | -- | -189.70% |
| Earnings from Discontinued Operations | 519.76% | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -119.84% |
| Net Income | 8,995.09% | 65.91% | 7.42% | -- | -124.85% |
| EBIT | 38.59% | -236.16% | -7.47% | -- | -1,925.51% |
| EBITDA | 39.67% | -254.47% | -7.55% | -- | -682.50% |
| EPS Basic | 9,033.33% | 66.67% | 6.06% | 97.78% | -125.00% |
| Normalized Basic EPS | 75.00% | 68.75% | -127.59% | -- | -366.67% |
| EPS Diluted | 9,033.33% | 66.67% | 6.06% | 97.78% | -125.00% |
| Normalized Diluted EPS | 75.00% | 68.75% | -127.59% | -- | -366.67% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |